FOR YOUR ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

Change the course
of disease

Go beyond the skin.*
Proven to preserve the joint.^†

*TREMFYA^® was approved in 2017 for use in adult patients with moderate to severe plaque
psoriasis, and was approved in 2020 for use in adult patients with active psoriatic arthritis.

At Week 24 in adult patients with active PsA:

Primary endpoint in pivotal studies: TREMFYA^® showed a greater clinical response in ACR20 vs placebo, in both the DISCOVER 1 (52% vs 22%) and DISCOVER 2 (64% vs 33%) trials, respectively (P<0.0001).¹

Major secondary endpoint in DISCOVER 2: TREMFYA^® showed a reduction in structural damage progression (LS mean change from baseline in total mvdH-S score) vs placebo (0.52 vs 0.95; P=NS).²

Primary endpoint in a phase 3b study (APEX): TREMFYA^® showed a greater clinical response in ACR20 vs placebo (68% vs 47%; P<0.001).^3,4‡§

^†Major secondary endpoint in a phase 3b study (APEX): TREMFYA^® showed a greater reduction in structural damage progression (LS mean change from baseline in total mvdH-S score) vs placebo (0.54 vs 1.35; P<0.001).^3,4§II¶

See the DISCOVER data

See the APEX data

ACR20=20% improvement in American College of Rheumatology composite measures of arthritis; ANCOVA=analysis of covariance; CMH=Cochran-Mantel-Haenszel; LS=least squares; mFAS=modified full analysis set; mvdH-S=modified van der Heijde-Sharp; ND/MD=natural disaster/major disruption; NS=not significant.

^‡The primary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used
to determine statistical significance. Statistics are based on the CMH test across multiply imputed datasets.

^§Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to support key study operations due to major disruptions.

^IIStatistics are based on ANCOVA. Missing data and data impacted by ND/MD were imputed using multiple imputation.

^¶Major secondary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and
can be used to determine statistical significance. Statistics are based on ANCOVA across multiply imputed datasets.

Go beyond the skin.* Proven to preserve the joint.^†

Provides Durable
Improvement Across Domains

TREMFYA^® provides the opportunity for durable improvement across joint and multiple key domains of active PsA in adult patients (DISCOVER 1 and DISCOVER 2).^2,5-8

Open-label active treatment NRI post hoc analysis at Week 100.

See DISCOVER 1 and DISCOVER 2 data

Structural Damage Data

New data are available from the APEX study showing joint improvement and preservation with TREMFYA^®.^3,4

See APEX data

Safety Profile in
Psoriatic Disease^‡

TREMFYA^® has a proven safety profile across psoriatic disease with 5 years of data in adult patients with moderate to severe plaque psoriasis (PsO) and 2 years of data in adult patients with active PsA.^1,5

See safety details

A Differentiated
Mechanism

Selective IL-23 inhibitors like TREMFYA^®
block IL-23 and regulate IL-17A/F and IL-22 cytokines.^1§

TREMFYA^® is the only^II selective, dual-acting^¶ IL-23i designed also to neutralize inflammation at its cellular source by binding to CD64.^9§#

^§The clinical significance is unknown.

^IIBased on approved IL-23 inhibitors for active PsA as of October 2025.

^¶Dual-acting is defined as blocking IL-23 and binding to CD64.

^#Findings are limited to in vitro studies.

See MOA details

Access options for all patients, and dedicated patient support

See access details

CD64=cluster of differentiation 64; IL-17A=interleukin-17A; IL-17F=interleukin-17F; IL-22=interleukin-22; IL-23=interleukin-23; IL-23i=interleukin-23 inhibitor; NRI=nonresponder imputation.

*TREMFYA^® was approved in 2017 for use in adult patients with moderate to severe plaque psoriasis, and was approved in 2020 for use in adult patients with active psoriatic arthritis.

^†Major secondary endpoint in a phase 3b study (APEX): TREMFYA^® showed a greater reduction in structural damage progression (LS mean change from baseline in total mvdH-S score) vs placebo (0.54 vs 1.35; P<0.001).^3,4^**^††‡‡

^‡Psoriatic disease is defined as moderate to severe plaque PsO and active PsA.

**Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to support key study operations due to major disruptions.

^††Statistics are based on ANCOVA. Missing data and data impacted by ND/MD were imputed using multiple imputation.

^‡‡Major secondary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used to determine statistical significance. Statistics are based on ANCOVA across multiply imputed datasets.

“…I know how my active PsA symptoms felt before and I know how much of my life I missed out on because of that. And, honestly, I can tell you that my worst day now is my best day then._“

- Suzana, real TREMFYA^® patient

Woman in a white shirt looking down at a laptop

Access options for all patients, regardless of insurance coverage

95%* nationally preferred^† first-line commercial coverage

No step edit required^‡

ONCE A PRESCRIBING DECISION HAS BEEN MADE

See coverage & support

Source: Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of September 2025. Collected as of 09/25 and may change.

*These percentages may not represent 100% of formulary lives due to data limitations.

^†“Preferred” means TREMFYA^® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.

^‡“No Step Therapy”: This plan does not require the patient to step through and fail an alternate product before this product is dispensed.

Explore dedicated patient support

Request local rep

References: 1. TREMFYA^® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 3. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Abstract presented at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. Late-Breaking Abstracts Session II. 4. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Oral presentation at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. 5. Data on file. Janssen Biotech, Inc. 6. McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475-485. 7. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 8. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125. 9. Krueger J, Eyerich K, Greving C, et al. Differentiation of therapeutic antibodies targeting IL‍-‍23. Poster presented at: 2022 Society for Investigative Dermatology; May 18-‍21, 2022; Portland, OR.